Skip to main content
SpringerLink
Log in

Personalized Best: Toward Improving Care in Ulcerative Colitis

  • Multicenter Seminars: IBD (MUSE: IBD)
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Barnes EL, Jiang Y, Kappelman MD et al. Decreasing Colectomy Rate for Ulcerative Colitis in the United States between 2007 and 2016: A Time Trend Analysis. Inflamm Bowel Dis 2020;26:1225–1231.

    PubMed  Google Scholar 

  2. Argollo M, Kotze PG, Kakkadasam P et al. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702–710.

    Article  Google Scholar 

  3. Denson LA, Curran M, McGovern DPB et al. Challenges in IBD Research: Precision Medicine. Inflamm Bowel Dis 2019;25:S31-s39.

    Article  Google Scholar 

  4. Sazonovs A, Kennedy NA, Moutsianas L et al. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease. Gastroenterology 2020;158:189–199.

    Article  CAS  Google Scholar 

  5. Suris Marin G, Santacana E, Padullés N et al. P264 Impact of the HLA-DQ1*05 alelle on the initial response to infliximab in patients with Inflammatory Bowel Disease. Journal of Crohn’s and Colitis 2021;15:S301–S302.

    Article  Google Scholar 

  6. Wilson A, Peel C, Wang Q et al. HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:356–363.

    Article  CAS  Google Scholar 

  7. Guardiola Capón J, SERRA K, Rodríguez-Alonso L, et al. P711 Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to adalimumab in patients with Crohn’s disease. Journal of Crohn's and Colitis 2020;14:S574-S574.

  8. Panaccione R, Ghosh S, Middleton S et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400.e3.

    Article  CAS  Google Scholar 

  9. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383–1395.

    Article  CAS  Google Scholar 

  10. Raine T, Kennedy NA. Immunomodulator and Biologic Combination Therapy in IBD: The Debate That Just Won’t Go Away? J Crohns Colitis 2020;14:1343–1344.

    Article  Google Scholar 

  11. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014;146:681–688 e1.

  12. Matsumoto T, Motoya S, Watanabe K et al. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective. Randomized Trial. J Crohns Colitis 2016;10:1259–1266.

    Article  Google Scholar 

  13. Elias ED, Targownik LE, Singh H et al. A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD. Inflamm Bowel Dis 2020;26:150–157.

    Article  Google Scholar 

  14. Yang SK, Hong M, Baek J et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014;46:1017–1020.

    Article  CAS  Google Scholar 

  15. Fiocchi C, Dragoni G, Iliopoulos D, et al. Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD - what, why, and how. J Crohns Colitis 2021. epublished March 18, 2021.

Download references

Funding

This research was supported by grants from the National Institutes of Health [K23DK127157-01 ELB].

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, University of North Carolina At Chapel Hill, Campus Box #7080, 130 Mason Farm Road, Chapel Hill, NC, 27599-7080, USA

    Nannaya Jampala, Animesh Jain, Hans H. Herfarth, Millie D. Long, Kimberly N. Weaver & Edward L. Barnes

  2. Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA

    Nannaya Jampala, Animesh Jain, Hans H. Herfarth, Millie D. Long, Kimberly N. Weaver & Edward L. Barnes

Authors
  1. Nannaya Jampala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Animesh Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans H. Herfarth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Millie D. Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kimberly N. Weaver
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Edward L. Barnes
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Hans H. Herfarth has served as a consultant for Alivio, AMAG, BMS, ExeGI, Finch, Janssen, Gilead, Lycera, Merck, Otsuka, Pfizer, PureTech, Seres, and research support from Pfizer and Artizan Biosciences. Millie D. Long has served as a consultant for AbbVie, UCB, Takeda, Janssen, Pfizer, Salix, Valeant, and Target Pharmasolutions and has received research support from Pfizer and Takeda. Kimberly N. Weaver has served as a consultant for AbbVie. Edward L. Barnes has served as a consultant for AbbVie, Takeda, and Target Pharmasolutions.

Corresponding author

Correspondence to Edward L. Barnes.

Ethics declarations

Conflict of interest

Nannaya Jampala and Animesh Jain have no relevant disclosures for this work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jampala, N., Jain, A., Herfarth, H.H. et al. Personalized Best: Toward Improving Care in Ulcerative Colitis. Dig Dis Sci 66, 3736–3739 (2021). https://doi.org/10.1007/s10620-021-07221-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-021-07221-w

Keywords

Search

Navigation